ReviewSeminars in hematology2011
Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Review in Seminars in hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Can Targeting Hypoxia-Mediated Acidification of the Bone Marrow Microenvironment Kill Myeloma Tumor Cells?Frontiers in oncology · 2021Pooled it
- Opportunities to Avoid Invasive Cancer by Diagnosis and Interception of Preneoplastic Lesions and Cancer Risk Conditions.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Molecular and immunological determinants of long-term survival in multiple myeloma.Blood advances · 2025Review
- Single-cell proteomic analysis reveals Multiple Myeloma heterogeneity and the dynamics of the tumor immune microenvironment in precursor and advanced states.Neoplasia (New York, N.Y.) · 2025Article
- Screening for monoclonal gammopathies of undetermined significance: A prospective study.Journal of public health in Africa · 2025Article
- Targeting the Inflammation-Metabolism Axis in MGUS: Causal Roles of CXCL10 Mediated by Blood Metabolites.Mediators of inflammation · 2025Article
- Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.International journal of molecular sciences · 2024Article
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.Blood cancer journal · 2024Article
- The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.Journal of experimental & clinical cancer research : CR · 2024Review
- Proteomic signatures improve risk prediction for common and rare diseases.Nature medicine · 2024Article
- From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma.Heliyon · 2024Review
- Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials.Journal of personalized medicine · 2024Review
- Transoral balloon kyphoplasty in a myeloma patient with painful osseous destruction of the corpus vertebrae axis.Journal of surgical case reports · 2024Article
- The network structure of hematopoietic cancers.Scientific reports · 2023Article
- Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS).Cancer causes & control : CCC · 2023Article
- Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy.International journal of hematology · 2023Review
- Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives.Pharmaceutics · 2022Review
- Multi-trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance.Hematological oncology · 2022Article
- Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance.Frontiers in immunology · 2022Review
- A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Monoclonal gammopathy of undetermined significance (MGUS), including immunoglobulin light chain only MGUS, is an age-dependent premalignant tumor that is present in about 4% of Caucasian individuals over the age of 50 years. It is comprised of two different kinds of tumors: about 15% lymphoid or lymphoplasmacytoid MGUS and the remainder plasma cell MGUS. Plasma cell MGUS is stable but can sporadically progress to multiple myeloma (MM) at an average rate of about 1% per year. Most, if not all, MM tumors are preceded by plasma cell MGUS, which shares four partially overlapping oncogenic features with MM. It presently is not possible to unequivocally distinguish an MGUS tumor cell from an MM tumor cell. However, two models based on clinical laboratory tests indicate that it is possible to stratify MGUS tumors into groups that have average rates of progression as low as 0.26% per year and as high as 12% per year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.